000			04642nam a22003855i 4500
001			394002
003			ES-MaUEC
005			20230102123046.0
007			cr nn 008mamaa
008			220920s2022 sz | s |||| 0|eng d
020			_a9783031084157
024	7		_a10.1007/978-3-031-08415-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC
245	1	0	_aMessenger RNA Therapeutics _cedited by Stefan Jurga, Jan Barciszewski
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XII, 446 páginas) _b68 ilustraciones, 57 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aRNA Technologies _x2197-9758 _v13
505	0		_aThe Democratization of RNA Therapeutics -- Supramolecular Strategies for mRNA Delivery -- In Vitro-Transcribed mRNAs as a New Generation of Therapeutics in the Dawn of 21st Century: Exploitation of Peptides as Carriers for their Intracellular Delivery -- Effective Delivery of mRNA Therapeutics and Vaccines Using Lipid Nanoparticles -- Messenger RNA Therapeutics -- Formulation, Delivery and Application of mRNA Therapeutics In Respiratory Diseases -- Clinical Applications of mRNA Formulated In Lipid Nanoparticles -- Preparation of Messenger RNA Loaded Nanomedicine Applied on Tissue Engineering And Regenerative Medicine -- Lipid Nanoparticle-Mediated Delivery of mRNA Therapeutics: Immune Activation By Ionizable Cationic Lipids -- Adjuvants, the Elephant in the Room for RNA Vaccines -- Addressing Skin with Modified mRNA Constructs for Novel Therapies -- mRNA-Based Cancer Immunotherapies -- From Bench to Bedside: The Journey of an mRNA Drug Candidate Into a Medicine -- Synthetic mRNA Gene Therapies for Chronic HBV Infection -- Delivery Vehicles for Self-Amplifying RNA -- Delivery Technologies of mRNA Vaccines -- Nanosystems: The Key in Formulations of mRNA for Several Pathologies -- Messenger RNA Nanoformulation For Cancer Vaccine -- Preparation of Synthetic mRNAs for In Vivo Applications - Overview and Considerations -- Messenger RNA for Prophylaxis -- Nuclear Export of mRNA with Disease Pathogenesis and Therapeutic Potentials -- Messenger RNA Therapeutics: Start of a New Era in Medicine -- mRNA Delivery Technologies for Therapeutic Applications.
520			_aThis book focuses on the fundamentals and applications of messenger RNA (mRNA)-based therapeutics and discusses the strengths and key challenges of this emerging class of drugs. In the past 30 years, extensive research and technological development in many areas have contributed to the emergence of in vitro transcribed mRNA as a therapeutic that has now reached clinical testing. Formulations that protect the mRNA from nucleases and accelerate its cellular uptake, combined with improvements to the mRNA molecules themselves, have been critical advancements for mRNAs to become viable therapeutics. Though once regarded as a serious impediment, the transient nature of mRNA technology is now considered a major advantage in making mRNA therapies safe and, ultimately, a potential game changer in the field of medicine. This new book in the RNA Technologies series provides a state-of-the-art overview on the emerging field of mRNA therapeutics covering essential strategies for formulation, delivery, and application. It also reviews the promising role in cancer immunotherapy, respiratory diseases, and chronic HBV infection and discusses RNA vaccines in light of the current COVID-19 pandemic. mRNA-based approaches have great potential to revolutionize molecular biology, cell biology, biomedical research, and medicine. Thus, this handbook is an essential resource for researchers in academia and industry contributing to the development of this new area of therapeutics.
700	1		_aJurga, Stefan _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aBarciszewski, Jan _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783031084140
776	0	8	_iPrinted edition: _z9783031084164
776	0	8	_iPrinted edition: _z9783031084171
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-08415-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_BiomedLife_2022
999			_c394002 _d394002